Levodopa/Carbidopa/Entacapone Eg

Levodopa, the active ingredient in Levodopa/Carbidopa/Entacapone Eg, is a Levodopa/Carbidopa/Entacapone combination presented as a tablet for oral use. It treats Parkinson's disease in adults by restoring dopaminergic activity in the brain.

GNH USA supplies Levodopa/Carbidopa/Entacapone Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used within the antiparkinson therapeutic class to manage motor symptoms of Parkinson's disease and related fluctuations. - Parkinson's disease: improves overall motor function and reduces rigidity and bradykinesia. - Parkinson's disease with motor fluctuations: prolongs the duration of levodopa effect and lessens OFF periods. - Adjunct therapy in early Parkinson's disease: enhances central dopaminergic activity when levodopa alone is insufficient.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually self‑limiting. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements. - Hallucinations: visual or auditory perceptual disturbances. - Severe hypotension: marked drop in blood pressure with risk of fainting. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Anaphylaxis: acute allergic response requiring immediate medical attention.

Levodopa/Carbidopa/Entacapone requires careful monitoring to ensure safe use. - Blood pressure monitoring: watch for orthostatic hypotension, especially during dose titration. - Psychiatric assessment: observe for hallucinations, confusion, or mood changes. - Renal function evaluation: adjust therapy in patients with significant renal impairment. - Discontinuation caution: avoid abrupt cessation to prevent withdrawal or worsening of symptoms. - Elderly patients: start at low dose and titrate slowly due to increased sensitivity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Selective MAO‑B inhibitors (e.g., selegiline): may cause severe hypertension. - Antipsychotics with strong dopamine blockade (e.g., haloperidol): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors. - Iron or antacid supplements: may decrease levodopa absorption; separate dosing by at least 2 hours.